Compare General Dynamics Corporation (GD) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Moderna, Inc. — how do they compare? General Dynamics Corporation trades at $331.27 (market cap $89.26B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: General Dynamics Corporation and Moderna, Inc. are close in size by market cap, and General Dynamics Corporation pays a 1.93% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Moderna, Inc. for 59 Days on average.
| GD | MRNA | |
|---|---|---|
Market Cap | $89.26B | $78.65B |
Volume | 1,496,273 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $395.97 | $203.46 |
52-Week Low | $312.53 | $22.36 |
Typical Hold Time | 85 Days | 59 Days |
Enterprise Value | $94.40B | $74.80B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $331.27, up 1.42% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 8.18% net margins and 17.8% ROE. Recent defense spending trends and analyst consensus of $420.57 price target suggest upside potential despite current technical weakness.
GD presents a compelling value opportunity with consistent earnings beats and strong defense sector tailwinds. Key risks include defense budget volatility and competitive pressures, but the company's $1.59 dividend and improving cash flow trends support the bullish analyst outlook. The stock's current discount to consensus target offers potential for appreciation.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
